Status:
NOT_YET_RECRUITING
Cilostazol in Parkinson's Disease
Lead Sponsor:
Ain Shams University
Conditions:
Parkinson's Disease
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Parkinson's disease is the second most common neurodegenerative diseases. The conventional treatment for PD has included dopaminergic treatment as Levodopa\\carbidopa or dopamine agonists, anti-cholin...
Detailed Description
Parkinson's disease (PD) is the second most common neurodegenerative disease, affecting about 1% of the elderly population, with 5 to over 35 new cases in 100,000 per year diagnosed with PD, with a pr...
Eligibility Criteria
Inclusion
- -Adult patients.
- Both males and females will be included
- Diagnosed Parkinson's disease according to the MDS criteria 2015
- At least 5 years of disease duration
- On stable Levodopa\\carbidopa regimen for the past 6 months.
- Clinically diagnosed with dyskinesia
Exclusion
- -Secondary causes of Parkinsonism
- Atypical parkinsonian syndromes
- Active malignancy
- Known intolerance or hypersensitivity to cilostazol
- Participation in other interventional trials
- Patients with hepatic (AST and ALT more than 3 times the upper normal limit) or renal impairment (eGFR less than 60 ml\\min).
- Patients receiving warfarin, other anti-coagulants or anti-platelet therapy.
- Patients with Congestive heart failure.
Key Trial Info
Start Date :
October 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06612593
Start Date
October 1 2024
End Date
October 1 2025
Last Update
September 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University Hospital
Cairo, Egypt